Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy

Review

(8339) Total Article Views

Authors: Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino, et al

Published Date January 2010 Volume 2010:2 Pages 7 - 19

DOI: http://dx.doi.org/10.2147/DHPS.S6270

Mary Elizabeth Cox¹, Jennifer Rowell¹, Leonor Corsino¹, Jennifer B Green^1,2

¹Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; ²Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USA

Abstract: Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.

Keywords: type 2 diabetes, pharmacotherapy, DPP-4 inhibitor, sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin

Other articles by Dr Jennifer Green

Readers of this article also read: